Table 1 Baseline characteristics
Characteristic | Whole cohort | SMART | SMART–START |
|---|---|---|---|
N = 31 | N = 17 | N = 14 | |
Median age (range) | 75 (56–93) | 82 (73–93) | 67 (56–78) |
< 75, n (%) | 13 (41.9%) | 1 (5.9%) | 12 (85.7%) |
≥ 75, n (%) | 18 (58.1%) | 16 (94.1%) | 2 (14.3%) |
Male sex, n (%) | 18 (58.1%%) | 8 (47.1%) | 10 (71.4%) |
ECOG ≥ 2, n (%) | 17 (54.8%) | 8 (47.1%) | 9 (64.3%) |
Stage, n (%) | |||
I–II | 11 (35.5%) | 7 (41.2%) | 4 (28.6%) |
III–IV | 20 (64.5%) | 10 (58.8%) | 10 (71.4%) |
No. EN sites, n (%) | |||
< 2 | 17 (54.8%) | 11 (64.7%) | 6 (42.9%) |
≥ 2 | 14 (45.2%) | 6 (35.3%) | 8 (57.1%) |
Elevated S-LDH, n (%) | 19 (61.3%) | 11 (64.7%) | 8 (57.1%) |
IPI, n (%) | |||
0–2 | 11 (35.5%) | 7 (41.2%) | 4 (28.6%) |
3–5 | 20 (64.5%) | 10 (58.8%) | 10 (71.4%) |
B-symptoms, n (%) | 7 (22.6%) | 4 (23.5%) | 3 (21.4%) |
Bulky disease ≥ 7.5 cm, n (%) | 9 (29.0%) | 6 (35.3%) | 3 (21.4%) |
Cell of origin, n (%) | |||
GCB | 7 (22.6%) | 0 (0%) | 7 (50%) |
Non-GCB | 24 (77.4%) | 17 (100%) | 7 (50%) |